NSB 0.00% 3.8¢ neuroscientific biopharmaceuticals ltd

Ms, glaucoma, alzeimers and spinal damage are the main targets...

  1. 234 Posts.
    lightbulb Created with Sketch. 4
    Ms, glaucoma, alzeimers and spinal damage are the main targets this drug has shown promise for I think they are also targeting other diseases
 
watchlist Created with Sketch. Add NSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.